Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 College of DuPage students ... gaining invaluable real-world experiences while serving biophysics internships at ... The students will be working as a part ... at IIT. The internship came about from a ... Physics; Dr. Kathy Finan , Biology; and Dr. ...
(Date:7/2/2015)... Scotland , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen ... to help it move to Office 365. ... provides small to medium-sized companies in the bio-tech ... all aspects of the purchasing cycle to help them ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... announced today the acquisition of Turner Medical, Inc ., thus becoming a ... to the Spine Industry. The acquisition of Turner Medical ideally supplements In’Tech Medical’s ...
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
Breaking Biology Technology:COD Students Participate in Prestigious Summer Internships 2Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... Corporation, a company enabling a new generation of molecular ... Mo lecule A rray (SiMoA ™ ) ... measure biomarkers of inflammation from patients with Crohn,s disease. ... was possible using Quanterix,s high sensitivity digital ELISA, allowed ...
... small package. For instance, these tiny cylinders of carbon ... than a metal conductor of the same size. It,s ... future nanoscale electronics. Butnot so fast. Recent tests ... suggest device reliability is a major issue. Copper ...
... CBI is pleased to announce the full agenda for ... being held September 20-22, 2011 in Philadelphia, PA. The ... from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, Merck, NIH, ... Attendees have the opportunity to customize their congress experience ...
Cached Biology Technology:Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease 2NIST uncovers reliability issues for carbon nanotubes in future electronics 2FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... implant such as a new hip or pacemaker with nanosized ... the University of Gothenburg, Sweden, can now explain why: they ... the International Journal of Nanomedicine . "Activation of ... common reasons for an implant being rejected," explains Professor Hans ...
... of ageing on the immune system received a boost ... (BBSRC) announced investment in a new 3.6 million research ... from the Babraham Institute with partners from the University ... The team hopes to illuminate a fundamental but little ...
... Livermore National Laboratory Geochemist Tom Guilderson has been ... prestigious Ernest Orlando Lawrence Award, Energy Secretary Steven ... for ground-breaking radiocarbon measurements of corals, advancements in ... processes revealing past climate variability, and the explanation ...
Cached Biology News:Cobblestones fool innate immunity 2New research aims to shed light on how aging affects immunity 2New research aims to shed light on how aging affects immunity 3Geochemist Tom Guilderson wins E.O. Lawrence Award for radiocarbon work 2
FRACTALKINE [Human] (Recombinant)...
... Operating head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps ... ... ... ...
... System with the xPONENT Software Interface ... multi-analyte assays using Upstate's Beadlyte® reagents. ... user friendly xPONENT software developed by ... templates for commercial or home-made multiplex ...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
Biology Products: